1. At a Glance
Vijaypd Ceutical, a pharma distributor born in 1971, is going SME with a ₹19.25 Cr fixed-price IPO at ₹35/share. The lot size is a heavyweight 4,000 shares. Retail investors must cough up ₹2.8 lakh (min 2 lots)—so forget your chai-samosa SIP crowd; only serious bidders allowed. HNIs? ₹4.2 lakh minimum. Listing is set for NSE SME on Oct 7, 2025.
What’s juicy? FY25 revenue doubled to ₹107.6 Cr from ₹54.3 Cr in FY24, while PAT nearly tripled to ₹4.8 Cr. Debt has slimmed down from ₹30 Cr to ₹21.7 Cr, but leverage still lurks. Promoters are diluting from 78% to 56%, a chunky 22% drop. Why? To fund their API/intermediates plant in MIDC Ahmednagar (₹10.8 Cr capex), repay ₹5.1 Cr loans, and of course, “general corporate purposes” (aka the IPO’s samosa budget).
So the pitch is clear: from distributor of 19,000 SKUs to manufacturer of APIs. Big leap, but can a ₹20 Cr raise turn a 50-year-old distributor into a manufacturing contender?
2. Introduction
Let’s be honest—“Vijaypd Ceutical” sounds like the pharma cousin of your neighborhood Kirana store: “aapko tablet chahiye ya shampoo?” And that’s not far from reality. They’re stockists, agents, packers, distributors—serving 2,109 pharmacies, clinics, and nursing homes across 20 locations.
But here’s the twist: they want to climb the pharma value chain. Instead of just supplying other people’s drugs, they now want to make their own APIs and intermediates. IPO money = land, plant, machinery at MIDC Shrirampur.
This isn’t a vanity project. Margins in distribution are razor-thin (EBITDA margin FY25 = 8%), but in APIs, if executed well, margins can skyrocket. The risk? Manufacturing is a different beast—compliance, R&D, process chemistry, scale economics. Going from middleman to manufacturer is like a delivery boy deciding to run a cloud kitchen—doable, but not guaranteed.
3. Business Model – WTF Do They Even Do?
Currently, Vijaypd Ceutical is a pharma and FMCG distributor with:
- Products: medicines, vitamins, enzymes, diagnostics kits, baby care, ayurvedic, cosmetics, food products.
- Network: over 2,100 pharmacies & hospitals, 170+ manufacturers tied up, 19,000+ SKUs.
- Certifications: FDA, FSSAI, BMC—legit paperwork, not WhatsApp approvals.
Revenue = distributor commissions and margins on stock. Nothing fancy.
But post-IPO plan = API/intermediates manufacturing unit at MIDC Ahmednagar. This
